SG10201911221RA - Bicyclic heteroaryl derivatives as cftr potentiators - Google Patents

Bicyclic heteroaryl derivatives as cftr potentiators

Info

Publication number
SG10201911221RA
SG10201911221RA SG10201911221RA SG10201911221RA SG10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA
Authority
SG
Singapore
Prior art keywords
bicyclic heteroaryl
heteroaryl derivatives
cftr potentiators
potentiators
cftr
Prior art date
Application number
SG10201911221RA
Other languages
English (en)
Inventor
Joseph Strohbach
David Limburg
John Mathias
Atli Thorarensen
James Mousseau
Rajiah Denny
Christoph Zapf
Ivan Efremov
Original Assignee
Cystic Fibrosis Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found filed Critical Cystic Fibrosis Found
Publication of SG10201911221RA publication Critical patent/SG10201911221RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201911221RA 2016-12-16 2017-12-14 Bicyclic heteroaryl derivatives as cftr potentiators SG10201911221RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
SG10201911221RA true SG10201911221RA (en) 2020-02-27

Family

ID=62557188

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201911076QA SG10201911076QA (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators
SG10201911221RA SG10201911221RA (en) 2016-12-16 2017-12-14 Bicyclic heteroaryl derivatives as cftr potentiators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201911076QA SG10201911076QA (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Country Status (11)

Country Link
US (4) US10131670B2 (zh)
EP (1) EP3554506B1 (zh)
JP (1) JP7150721B2 (zh)
CN (1) CN110300589B (zh)
AU (2) AU2017378324B2 (zh)
BR (1) BR112019012335A2 (zh)
CA (1) CA3046968A1 (zh)
MX (1) MX2019007135A (zh)
RU (1) RU2753056C2 (zh)
SG (2) SG10201911076QA (zh)
WO (1) WO2018112149A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102336926B1 (ko) 2014-10-06 2021-12-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제
MX2018006287A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc de triazol y usos de los mismos.
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
PT3380480T (pt) 2015-11-25 2023-03-14 Gilead Apollo Llc Inibidores de pirazol acc e seus usos
PL3519401T3 (pl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator mukowiscydozowego przezbłonowego regulatora przewodnictwa, kompozycje farmaceutyczne, sposoby leczenia i proces wytwarzania modulatora
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
IL273831B1 (en) 2017-10-19 2024-06-01 Vertex Pharma Crystal forms and preparations of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MA51828B1 (fr) 2018-02-15 2022-11-30 Vertex Pharma Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CN113891744A (zh) * 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
JP2022541178A (ja) 2019-07-15 2022-09-22 ノバルティス アーゲー (s)-3-アミノ-6-メトキシ-n-(3,3,3-トリフルオロ-2-ヒドロキシ-2-メチルプロピル)-5-(トリフルオロメチル)ピコリンアミド製剤
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
US20230277550A1 (en) 2020-08-20 2023-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
MX2008007103A (es) 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
JP5512975B2 (ja) * 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
CA2647391C (en) * 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
SI2531187T1 (sl) * 2010-02-05 2016-01-29 Adverio Pharma Gmbh Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze
UY34484A (es) * 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US11352359B2 (en) * 2013-07-02 2022-06-07 Rhizen Pharmaceuticals Ag PI3K protein kinase inhibitors
KR20230146104A (ko) 2016-11-18 2023-10-18 시스틱 파이브로시스 파운데이션 Cftr 강화제로서의 피롤로피리미딘

Also Published As

Publication number Publication date
AU2021277702A1 (en) 2021-12-23
EP3554506A1 (en) 2019-10-23
US20190016727A1 (en) 2019-01-17
SG10201911076QA (en) 2020-01-30
CN110300589A (zh) 2019-10-01
US10377762B2 (en) 2019-08-13
JP2020502103A (ja) 2020-01-23
JP7150721B2 (ja) 2022-10-11
AU2017378324A1 (en) 2019-06-27
US20180170938A1 (en) 2018-06-21
EP3554506B1 (en) 2021-04-28
RU2019120990A (ru) 2021-01-18
US20190330219A1 (en) 2019-10-31
EP3554506A4 (en) 2020-06-10
US10131670B2 (en) 2018-11-20
RU2019120990A3 (zh) 2021-01-18
CA3046968A1 (en) 2018-06-21
CN110300589B (zh) 2023-03-10
RU2753056C2 (ru) 2021-08-11
MX2019007135A (es) 2019-11-18
US20190016728A1 (en) 2019-01-17
AU2021277702B2 (en) 2023-11-30
US10208053B2 (en) 2019-02-19
US10766904B2 (en) 2020-09-08
WO2018112149A1 (en) 2018-06-21
AU2017378324B2 (en) 2021-09-02
BR112019012335A2 (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
SG10201911221RA (en) Bicyclic heteroaryl derivatives as cftr potentiators
IL266668B (en) Pyrrolopyrimidines as cftr enhancers
HRP20182073T1 (hr) Derivati kinoksalina korisni kao modulatori fgfr kinaze
IL246474A0 (en) Heteroaryl substituted nicotinamide compounds
HK1245249A1 (zh) 二環喹唑啉酮衍生物
EP3116858A4 (en) Azaspiro derivatives as trpm8 antagonists
SG11201805869XA (en) Quinolin-2-one derivatives
EP3253753A4 (en) Ergoline compounds and uses thereof
EP3440470A4 (en) SHOCK DETECTOR
EP3352758A4 (en) Deuterated cftr potentiators
EP3405455A4 (en) 2-oxindole CONNECTIONS
EP3434149A4 (en) CHILD BED THAT CAN BE REASSEMBLED
EP3269721A4 (en) Bicyclic pyridine compound
EP3150598A4 (en) Substituted tropane derivatives
IL281175A (en) Bicyclic heteroaryl derivatives
EP3449196A4 (en) VERTICAL CHIP DRYER
PT3319956T (pt) Derivados de oxopiridina substituída
AU2015902298A0 (en) Anti-fungal potentiators